^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    1d
    QL1706 Plus Lenvatinib in Previously Treated Penile Cancer (clinicaltrials.gov)
    P2, N=47, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab)
    4d
    SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
    P2, N=30, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    6d
    Case Report: PD-1/CTLA-4 dual checkpoint blockade(QL1706) in advanced pulmonary squamous cell carcinoma complicated by multidrug-resistant tuberculosis after multiple lines of immunotherapy. (PubMed, Front Oncol)
    We report a 56-year-old man with stage IVA pulmonary squamous cell carcinoma (SqNSCLC) who progressed on multiple lines of therapy, including chemotherapy plus pembrolizumab, docetaxel, and the PD-1/VEGF bispecific antibody ivonescimab. Crucially, strict multidisciplinary monitoring confirmed no TB reactivation or dissemination, and no grade ≥3 immune-related adverse events occurred. This case provides the first clinical evidence that, in carefully selected patients with controlled MDR-TB, dual checkpoint blockade with QL1706 is a feasible salvage strategy, provided that TB is rigorously managed.
    Review • Journal • Checkpoint inhibition
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Keytruda (pembrolizumab) • docetaxel • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab)
    10d
    STAR-03: A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=96, Recruiting, Shandong Provincial Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Qibeian (iparomlimab/tuvonralimab)
    15d
    Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Sun Yat-sen University
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    16d
    Case Report: Successful treatment of steroid-refractory immune checkpoint inhibitor associated myocarditis with tofacitinib. (PubMed, Front Immunol)
    This case report describes a 75-year-old female patient with deficient mismatch repair sigmoid colon adenocarcinoma who developed severe multi-organ irAEs, including myositis, hepatitis, and steroid-refractory myocarditis 25 days after receiving QL1706 (a PD-1/CTLA-4 bispecific antibody)...The clinical course was further complicated by endocrine involvement and hematological toxicity following second-line immunosuppression with mycophenolate mofetil...However, the significant infection risk underlines the necessity for vigilant monitoring and prophylactic strategies. Further prospective studies are needed to define the efficacy and safety of JAK inhibitors in this setting.
    Journal • Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    MSI-H/dMMR
    |
    Qibeian (iparomlimab/tuvonralimab) • tofacitinib
    17d
    A prospective, open-label, multicenter, phase II clinical study on postoperative chemotherapy combined with QL1706 for the treatment of high-risk triple-negative breast cancer (ChiCTR2600121774)
    P2, N=62, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    ER (Estrogen receptor)
    |
    Qibeian (iparomlimab/tuvonralimab)
    17d
    A prospective, single-arm clinical study of QL1706 monotherapy in elderly patients with driver gene-negative, PD-L1-positive NSCLC (ChiCTR2600121140)
    P=N/A, N=40, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Qibeian (iparomlimab/tuvonralimab)
    17d
    Real-world study of Iparomlimab and Tuvonralimab (QL1706)-based therapy for gastrointestinal tumors (ChiCTR2600121037)
    P=N/A, N=500, Nantong Tumor Hospital; Nantong Tumor Hospital
    New trial • Real-world evidence
    |
    Qibeian (iparomlimab/tuvonralimab)
    17d
    Conversion Therapy with Iparomlimab and Tuvonralimab in Combination with Lenvatinib and GEMOX for Potentially Resectable Locally Advanced Cholangiocarcinoma: A Single-Center, Prospective, Phase 2 Study (ChiCTR2600120552)
    P2, N=32, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P2 trial
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab)
    17d
    Iparomlimab and Tuvonralimab Combined with Bevacizumab and Chemotherapy for the Treatment of Recurrent Ovarian Clear Cell Carcinoma: A Single-Center, Single-Arm Clinical Study (ChiCTR2600120442)
    P=N/A, N=37, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    |
    Avastin (bevacizumab) • Qibeian (iparomlimab/tuvonralimab)
    17d
    A Single arm, phase II clinical study of QL1706 combined with Donafenib and hepatic arterial infusion chemotherapy (HAIC) as first-line treatment for unresectable biliary malignant tumors (ChiCTR2600120479)
    P2, N=32, Recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • Zepsun (donafenib)